Apolipoprotein B quantified by particle-concentration fluorescence immunoassay.
We have developed a particle-concentration fluorescence immunoassay (PCFIA) for estimating apolipoprotein (apo) B concentrations in plasma. A two-step antigen-detection system with a polyclonal antibody to apo B bound to carboxyl-polystyrene particles binds the antigen, and a fluorescein-labeled monoclonal antibody detects the bound apo B. Narrow-cut low-density lipoproteins (d = 1.03-1.05 kg/L) were used as the primary standard. The assay compares well with the enzyme-linked immunosorbent assay. The PCFIA gives parallel responses with low-density lipoprotein, very-low-density lipoproteins, and plasma samples, and can be fully automated and completed in 3 h. In a pilot study of patients with diabetes, coronary artery disease (CAD), or both, we found statistically significant differences in apo B concentrations for patients with both CAD and diabetes compared with those for patients with diabetes alone or for control subjects (P < 0.01).
Hallaway
B J
BJ
Atherosclerosis Research Unit, Mayo Clinic and Foundation, Rochester, MN 55905.
Rastogi
A
A
Kottke
B A
BA
D001055:Apolipoproteins B / Q000097:blood*; D003327:Coronary Disease / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D016650:Fluorescein-5-isothiocyanate; D005456:Fluorescent Dyes; D006801:Humans; D007118:Immunoassay / Q000379:methods* / Q000706:statistics & numerical data; D011786:Quality Control
D001055:Apolipoproteins B; D005456:Fluorescent Dyes; D016650:Fluorescein-5-isothiocyanate